LAUSR

The intestinal L-cell secretes a diversity of biologically-active hormones, most notably the glucagon-like peptides, GLP-1 and GLP-2. The highly-successful introduction of GLP-1-based drugs into the clinic for the treatment of patients with type 2 diabetes and obesity, and of a GLP-2 analog for patients with short bowel syndrome, has led to the suggestion that stimulation of the endogenous secretion of these peptides may serve as a novel therapeutic approach in these conditions. Situated in the intestinal epithelium, the L-cell demonstrates complex relationships with not only circulating, paracrine and neural regulators, but also ingested nutrients and other factors in the lumen, most notably the microbiota. The integrated input from these numerous secretagogues results in a variety of temporal patterns in L-cell secretion, ranging from minutes to 24-hours. This review combines the findings of traditional, physiological studies with those using newer molecular approaches to describe what is known and what remains to be elucidated after 5 decades of research on the intestinal L-cell and its secreted peptides, GLP-1 and GLP-2.